|3Feb 17, 6:27 PM ET

COHEN RICHARD M 3

3 · 20/20 Biolabs, Inc. · Filed Feb 17, 2026

Insider Transaction Report

Form 3
Period: 2026-02-17
Holdings
  • Series A-2 Preferred Stock

    [F1]
    Common Stock (7,700 underlying)
  • Stock Option

    [F2]
    Exercise: $0.82From: 2019-08-01Exp: 2029-07-31Common Stock (48,780 underlying)
  • Stock Option

    [F3]
    Exercise: $1.04From: 2021-01-28Exp: 2031-01-27Common Stock (76,628 underlying)
  • Stock Option

    [F4]
    Exercise: $1.06Exp: 2032-02-01Common Stock (37,584 underlying)
  • Stock Option

    [F5]
    Exercise: $1.06From: 2022-02-01Exp: 2032-02-01Common Stock (37,583 underlying)
  • Stock Option

    [F6]
    Exercise: $1.74Exp: 2033-01-01Common Stock (30,000 underlying)
  • Stock Option

    [F7]
    Exercise: $2.55Exp: 2034-07-01Common Stock (30,000 underlying)
Footnotes (7)
  • [F1]Each share of series A-2 preferred stock is convertible into one (1) share of common stock at any time at the option of the Reporting Person. In addition, all outstanding shares of series A-2 preferred stock shall automatically be converted into an equivalent number of shares of common stock on the date on which the Issuer's common stock is listed on a national stock exchange, including without limitation, the New York Stock Exchange or the Nasdaq Stock Market. The series A-2 preferred stock has no expiration date.
  • [F2]On August 1, 2019, the Reporting Person was granted a stock option for the purchase of 48,780 shares of common stock, which vested in full on the date of grant.
  • [F3]On January 28, 2021, the Reporting Person was granted a stock option for the purchase of 76,628 shares of common stock, which vested in full on the date of grant.
  • [F4]On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,584 shares of common stock, which vested in equal monthly installments over 12 months.
  • [F5]On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,583 shares of common stock, which vested in full on the date of grant.
  • [F6]On January 1, 2023, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.
  • [F7]On July 1, 2024, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.
Signature
/s/ Richard M. Cohen|2026-02-17

Documents

1 file
  • 3
    ownership.xmlPrimary